20-F: Psyence Biomedical Ltd. Files 20-F Report for Fiscal Year Ended March 31, 2024

Psyence Biomedical Ltd. releases its 20-F report, detailing financial performance and operational activities for the fiscal year ending March 31, 2024, highlighting a significant net loss due to listing expenses and ongoing clinical trial developments.

Summary

• Psyence Biomedical Ltd., a clinical-stage biotechnology company, has filed its 20-F report for the fiscal year ended March 31, 2024.
• The company reported a net loss of $50.96 million, primarily driven by a deemed listing expense of $41.48 million related to its business combination.
• Research and development expenses totaled $954,593, mainly for clinical trials of PEX010, a natural psilocybin product.
• The company is developing PEX010 for the treatment of Adjustment Disorder (AjD) in palliative care and has initiated a Phase IIb study in Australia.
• Psyence Biomedical relies on licensing agreements, particularly with Filament, for the supply of PEX010.
• The company expects current cash reserves and PIPE financing to fund operations beyond the next 12 months but may need additional funding.
• The report outlines various risks, including clinical trial failures, regulatory hurdles, competition, and intellectual property protection challenges.
• The company is pursuing regulatory approval via the 505(b)(2) pathway, potentially allowing for a shorter development program.
• The company is subject to healthcare laws and regulations, and failure to comply could result in penalties.
• The company is an emerging growth company and a foreign private issuer, which provides certain exemptions from U.S. reporting requirements.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there are positive aspects such as ongoing clinical trials and potential for expedited regulatory approval, the significant net loss and reliance on external funding raise concerns. The overall sentiment is cautiously optimistic but tempered by financial challenges and risks.

Positives

• The company is actively pursuing clinical trials for PEX010, a natural psilocybin product, to treat Adjustment Disorder (AjD) in palliative care.
• The company has secured a research IP agreement with Filament for the supply of PEX010.
• The company expects current cash reserves and PIPE financing to fund operations beyond the next 12 months.
• The company is pursuing regulatory approval via the 505(b)(2) pathway, potentially allowing for a shorter development program.
• The company received a research and development cash rebate of AUD $1,336,622 from the Australian government for the fiscal year ended June 30, 2023.

Negatives

• The company reported a significant net loss of $50.96 million for the fiscal year ended March 31, 2024.
• The company has a limited operating history and has not generated any revenue to date.
• The company relies on licensing agreements, particularly with Filament, for the supply of PEX010.
• The company may need additional funding sooner than planned.
• The company is subject to healthcare laws and regulations, and failure to comply could result in penalties.

Risks

• Clinical trial failures could prevent the company from obtaining regulatory approval for its product candidates.
• Regulatory hurdles and delays could significantly impact the development and commercialization of product candidates.
• Intense competition from other pharmaceutical and biotechnology companies could hinder the companys success.
• The company may face challenges in protecting its intellectual property rights.
• The company may experience difficulties in enrolling patients in clinical trials.
• Supply chain interruptions could delay the development of product candidates.
• The company may be subject to penalties under the Registration Rights Agreement since the Initial Resale Registration Statement was not declared effective in a timely manner, which could include liquidated damages, the acceleration of repayment under the First Tranche Notes and other penalties, which would materially and adversely affect our business.
• If we fail to meet applicable continued listing requirements, Nasdaq may delist our Common Shares from trading, in which case the liquidity and market price of our Common Shares could decline.

Future Outlook

The company intends to expand the development of its product candidates for additional indications beyond AjD in palliative care, including potential applications for Alcohol Use Disorder. The company is also engaging two alternative suppliers of drug product for its pivotal Phase III studies as well as for future studies in other indications.

Industry Context

The psychedelic therapy industry is relatively new and undergoing rapid growth, with increasing competition and the formation of strategic relationships. The company believes that its clinical asset has a first-mover advantage in both the palliative care and cancer-related AjD market upon approval.

Comparison to Industry Standards

• The company intends to submit the NDA requesting assessment via the 505(b)(2) pathway, which could potentially allow for a shorter development program compared to a regular NDA submission.
• In 2019, the FDA designated psilocybin therapy as breakthrough therapy for the treatment of severe depressive disorder, which provides the possibility that psilocybin-based drug candidates may be eligible for a number of processes that could result in expedited marketing approval.

Related Party Transactions

• The company issued an unsecured convertible promissory note to Psyence Group Inc. in the principal amount of $1,610,657.
• NCAC issued an unsecured convertible promissory note to the NCAC Sponsor in the principal amount of $1,615,501.

Stakeholder Impact

• Shareholders may experience volatility in the price of the company's securities.
• Employees may be affected by the companys ability to secure additional funding and maintain operations.
• Customers (patients) may benefit from the development of new treatments for Adjustment Disorder.
• Suppliers and creditors may be impacted by the companys financial performance and ability to meet its obligations.

Next Steps

• Continue Phase IIb clinical trial in Australia for PEX010.
• Potentially move to a Phase III trial in the United States, subject to FDA review.
• Expand the development of product candidates for additional indications beyond AjD in palliative care.
• Finalize supply agreements and licensing agreements with two licensed suppliers operating in the United Kingdom and North America.

Key Dates

Keywords

psilocybin, clinical trials, adjustment disorder, biotechnology, palliative care, PEX010, regulatory approval, financial results, Filament, research and development